Use of Medications for Opioid Use Disorder (MOUD) in Medicaid
Deaths from opioid overdoses surged to unprecedented levels during the COVID-19 pandemic. As of April 2021, 75,000 people died from opioid overdoses in the preceding 12 months, a 35-percent increase from the same period the year before. Access to medications that treat opioid use disorders (known as MOUD) is essential to address the high rates of opioid addiction and overdose mortality. Medicaid covers almost 40 percent of nonelderly adults with opioid use disorder (OUD), underscoring the key role that the program can play in providing access to MOUD. This study will examine the extent to which beneficiaries diagnosed with OUD receive MOUD in Medicaid.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|April 2022||Centers for Medicare and Medicaid Services||Use of Medications for Opioid Use Disorder (MOUD) in Medicaid||Office of Evaluation and Inspection||OEI-BL-22-00260||2023|